4/A: Celularity Director Ling Receives RSU Grant

Celularity Inc. Director Geoffrey Ling, M.D., reported the acquisition of 19,231 Class A common stock shares through immediately vesting restricted stock units.

Summary

• Geoffrey Ling, M.D., a Director at Celularity Inc. (CELU), acquired 19,231 shares of Class A Common Stock.
• The acquisition was made on January 12, 2026, through a grant of Restricted Stock Units (RSUs) under the Celularity Inc. 2021 Equity Incentive Plan.
• Each RSU represents a right to receive one share of the Issuer's Class A common stock, and these RSUs vested immediately upon grant.
• The transaction price for these RSUs was $0.00 per share.
• Following this transaction, Geoffrey Ling, M.D., beneficially owns a total of 256,026 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The grant of immediately vesting restricted stock units to a director is a positive sign of continued alignment between management and shareholder interests, reflecting standard compensation practices.

Positives

• The grant of 19,231 Restricted Stock Units (RSUs) to a director aligns management's interests with those of shareholders.
• The RSUs vested immediately upon grant, providing immediate ownership to the director.

Future Outlook

This filing is an insider transaction report and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

The grant of Restricted Stock Units to a director is a common practice across various industries for executive and director compensation, aiming to incentivize long-term performance and align interests with shareholders.

Comparison to Industry Standards

• Equity grants, such as Restricted Stock Units, are a standard component of director compensation packages in publicly traded companies across the biotechnology and healthcare sectors, similar to practices observed at companies like Gilead Sciences or Amgen.

Corporate Governance

Related Party Transactions

• The grant of 19,231 Restricted Stock Units to Geoffrey Ling, M.D., a director of Celularity Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant of equity to a director can enhance alignment between management and shareholder interests, potentially leading to better long-term performance.
• Employees: While not directly impacting general employees, such grants are part of a broader compensation philosophy that can influence overall company culture and retention strategies for key personnel.

Key Dates

Recommendation

This Form 4/A reports a routine equity grant to a director, which is a standard compensation practice and indicates continued insider ownership. It does not provide new fundamental information to alter an investment thesis, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Celularity Inc., CELU, Form 4/A, SEC filing, Restricted Stock Units, RSU, equity grant, insider transaction, director compensation, stock ownership